Good afternoon and thank you for standing by. Welcome to the Fluidigm Third Quarter 2021 Financial Results conference call. At this time all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. I would now like to hand the conference over to your speaker today, Mr. Peter DeNardo. Sir, please go ahead.

Thank you Ann. Good afternoon, everyone and welcome to the Fluidigm Third Quarter 2021 earnings conference call. At the close of market today, Fluidigm released its financial results for the quarter ended September 30th, 2021. During this call we will review our results and provide commentary on our financial and operational performance, market trends, and strategic initiatives. Presenting for Fluidigm today will be Chris Linthwaite, our President and CEO, and Vikram Jog, our CFO. During the call and subsequent Q&A session, we will make forward-looking statements about events and circumstances that have not yet occurred, including plans and projections for our business, future financial results, and market trends and opportunities. Examples include statements about expected financial performance, including guidance relating to revenues, net loss, and business line performance, as well as statements about strategic initiatives, cash and financing plans, market trends, product releases and customer demand, collaborations and partnerships, and revenue expectation. These statements are subject to substantial risks and uncertainties that may cause actual events or results to differ materially from current expectations. Information on these risks and uncertainties and other information affecting our business and operating results is contained on an annual report Form 10-K for the year ended December 31, 2020, as well as our other filings with the SEC. The forward-looking statements in this call are based on information currently available to us and Fluidigm disclaims any obligation to update these forward-looking statements, except as may be required by law. During the call, we will also present some financial information on a non-GAAP basis. Non-GAAP information is not prepared under a comprehensive set of accounting rules, and should only be used to supplement an understanding of the Company's operating results as reported our U.S. GAAP. We encourage you to carefully consider our results under GAAP, as well as our supplemental non-GAAP information, and the reconciliation between these presentations. Reconciliations between GAAP and non-GAAP operating results are presented in a table accompanying our earnings release, which can be found in the Investors section of our website. After conclusion of our prepared remarks, we will take questions from participants on today's call. I will now turn the call over to Chris, our President and CEO.

Thank you Peter, and good afternoon. In the third quarter we executed on our 3 part strategy to leverage the power of our core technologies. We saw a very active third quarter, and made progress on our ambitious plan to commercially scale 2 new instrument systems. Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our backlog of unfilled orders stands at more than $9 million, which is almost twice as much as our historic average. We expect to work through these pending orders over the next few quarters. Demand in the Asia - Pac region was impacted by China tax issues, and COVID related shutdowns in Japan. We felt strong demand from our Proteomics OEM partner Olink or for the new micro fluidic instrument designed and manufactured by Fluidigm. We delivered the first production units of the Olink signature Q100 benchtop instrument system, and we anticipate an increase in deliveries for Q4. We expect supply chain pressures to continue. Our teams are working diligently to mitigate these issues and are working directly with supply chain partners. However, this lack of visibility to supply chain reliability tempers our outlook for the near-term. We can also announced today that its Board of Directors is undertaking a review of various options with the assistance of outside financial, operating and legal advisors to maximize stockholder value. Included with regard to strategic alternatives, costs, and capital structure and operations and supply-chain. Please note, we will not be commenting further on these strategic alternatives today, nor can we take questions on this topic. Let's proceed to a review of the quarter. All of our activities track to the strategic pillars of innovation, partnerships, and beachhead expansion. I…

Thanks Chris, and good afternoon everyone. Before turning to our third quarter financial results, I would like to note that we have posted updated supplemental financial information in addition to our Investor presentation on our website. Let me begin with a review of financial and geographic highlights for the third quarter of 2021, and then provide updates to our 2021 guidance. Total revenue for the quarter was $28.5 million as compared to $39.9 million for Q3 2020. The year-over-year decline was primarily due to lower COVID-19 revenue, and lower development and grant revenue. Base product and service revenue, which excludes COVID-19 testing and other revenue, was $25.6 million, compared with $25.1 million for the year-ago period. In the third quarter, our base business recovery was tempered by supply chain disruptions and challenges in the Asia-Pacific region, resulting in revenue shortfalls in both of our franchises. Our backlog of unfilled orders at the end of the quarter was more than $9 million, which was about twice as much as historic levels. Outside of our base business, we saw stronger-than-expected revenue from. COVID-19 testing, which came in at $2.3 million as we have stated in the past, COVID-19 testing revenue continues to be highly volatile and may vary widely each quarter. With that being said, we currently believe that full-year COVID revenue will come in toward the high end of our device. As range of 12 to $13 million compared to our prior guidance of 10 to 13 million. In terms of the performance of each of our franchises mass cytometry product and service revenue of $15.8 million for the quarter was up 5% over the third quarter of 2020. These Microfluidics product and service revenue, which excludes COVID-19 testing revenue, was $9.4 million, or relatively flat compared to the $9.5 million…